The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has approved Altuvoct (efanesoctocog alfa) to be used to ...

Sobi’s Sanofi-partnered efanesoctocog alfa has been approved by the Medicines and Healthcare products Regulatory Agency (MHRA ...

That said, Sanofi launched once-weekly Altuviiio in the US in 2023 and Sobi has begun to launch in Europe (as Altuvoct) in 2024, and the product has a strong safety and efficacy profile.

The strategic portfolio includes Sobi's medicines Altuvoct, Aspaveli/Empaveli, Doptelet, Gamifant ®, Vonjo and Zynlonta ®, and royalty on Sanofi's sales of Altuviiio ® and Beyfortus.

L’Oreal OR-1.27%decrease; red down pointing triangle will sell part of its stake in Sanofi SAN-0.21%decrease; red down pointing triangle back to the French pharmaceutical company for 3 billion ...

AdvanCell has secured $112 million in a Sanofi Ventures-backed series C funding round as the Australian radiopharma company takes its lead candidate through a prostate cancer trial. The Pb-212 ...

Sanofi is planning a $5.12bn share buyback programme in 2025. Image credit: Shutterstock / JHVEPhoto. Sanofi has bought back a €3bn ($3.1bn) stake held by cosmetics giant L’Oréal, the first of ...

Sanofi (NASDAQ:SNY) Q4 2024 Earnings Call Transcript ... In hemophilia, an increasing number of patients switched to ALTUVIIIO from both factor and non-factor therapies. We're seeing strong ...

Sanofi’s sales rose 10% on a constant currency rate (“CER”) basis, while earnings per share declined 11%. Higher sales of Dupixent and contributions from new products like Altuviiio and ...

Sanofi delivered robust Q4 2024 results with strong growth across key products and new launches, including Dupixent and Beyfortus. The company’s strategic focus on R&D, pipeline productivity ...

Sanofi (NASDAQ: SNY) Q4 2024 Earnings Call Jan 30, 2025, 9:00 a.m. ET Read More: Earn up to $845 cash back this year just by changing how you pay at Costco! Learn more here. Contents: Prepared Remarks ...